Targeting cholesterol-dependent adrenal steroidogenesis for management of primary aldosteronism.
Hao Wu, Hongbo He, Tong Han...
https://pubmed.ncbi.nlm.nih.gov/39765399/Actively Recruiting
Led by Third Military Medical University · Updated on 2026-10-21
50
Participants Needed
1
Research Sites
N/A
Total Duration
Primary aldosteronism is a common cause of resistant high blood pressure. Researchers are comparing two treatment approaches to see how they affect aldosterone levels and other health markers in patients with this condition. The trial focuses on the use of inclisiran, a cholesterol-lowering drug, combined with amlodipine besylate, versus traditional statin therapy, aiming to find better management options for primary aldosteronism. Participants are randomly assigned to receive either inclisiran by injection plus oral amlodipine besylate and spironolactone, or oral statins combined with amlodipine besylate and spironolactone. The study compares these two regimens over a 24-week period to evaluate differences in aldosterone levels and other clinical measures. During the study, participants undergo regular monitoring of plasma aldosterone, blood pressure, plasma renin concentration, urinary aldosterone, serum potassium, lipid levels, and glucose. These assessments help researchers understand the treatments effects. The trial lasts 24 weeks after randomization, with careful follow-up to track changes in these important health parameters.
CONDITIONS
Comparing Inclisiran Versus Statin for Primary Aldosteronism
L
Liyuan Yuan
Z
Zhiming Zhu
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Third Military Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 weeks
Participants receive either inclisiran injections plus oral amlodipine besylate and spironolactone, or oral statins with amlodipine besylate and spironolactone.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hao Wu, Hongbo He, Tong Han...
https://pubmed.ncbi.nlm.nih.gov/39765399/Alessandro M Capponi
https://pubmed.ncbi.nlm.nih.gov/11893525/Elena Izkhakov, Yacov Shacham, Merav Serebro...
https://pubmed.ncbi.nlm.nih.gov/34198795/Eliano Pio Navarese, Michalina Kolodziejczak, Volker Schulze...
https://pubmed.ncbi.nlm.nih.gov/25915661/Rene Baudrand, Luminita H Pojoga, Anand Vaidya...
https://pubmed.ncbi.nlm.nih.gov/26432671/Third Military Medical University
Lead Sponsor